Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Ratjen

Showing results (311-320 of 326) with videos related to

Pageof 33
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 25, 2018
The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CFPaul D W Eckford, Jacqueline McCormack, Lise Munsie, et al.
The European Respiratory Journal|February 12, 2013
Consensus statement for inert gas washout measurement using multiple- and single- breath testsPaul D Robinson, Philipp Latzin, Sylvia Verbanck, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 24, 2022
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GISarah Jane Schwarzenberg, Phuong T Vu, Michelle Skalland, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 7, 2018
ECFS best practice guidelines: the 2018 revisionCarlo Castellani, Alistair J A Duff, Scott C Bell, et al.
American Journal of Respiratory and Critical Care Medicine|July 11, 2022
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for <i>F508del</i> and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled StudyMarcus A Mall, Rossa Brugha, Silvia Gartner, et al.
The Lancet. Respiratory Medicine|November 7, 2022
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsNicole Mayer-Hamblett, Felix Ratjen, Renee Russell, et al.
Pediatrics|November 23, 2021
Outcomes of Cystic Fibrosis Screening-Positive Infants With Inconclusive Diagnosis at School AgeTanja Gonska, Katherine Keenan, Jacky Au, et al.
American Journal of Respiratory and Critical Care Medicine|November 16, 2021
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical TrialDavid P Nichols, Alex C Paynter, Sonya L Heltshe, et al.
The Lancet. Respiratory Medicine|September 12, 2023
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspectiveNicole Mayer-Hamblett, John Paul Clancy, Raksha Jain, et al.
HGG Advances|November 17, 2022
High-quality read-based phasing of cystic fibrosis cohort informs genetic understanding of disease modificationScott Mastromatteo, Angela Chen, Jiafen Gong, et al.
Pageof 33

Showing results (311-320 of 326) with videos related to

Sort By:
Pageof 33
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 25, 2018
The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CFPaul D W Eckford, Jacqueline McCormack, Lise Munsie, et al.
The European Respiratory Journal|February 12, 2013
Consensus statement for inert gas washout measurement using multiple- and single- breath testsPaul D Robinson, Philipp Latzin, Sylvia Verbanck, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 24, 2022
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GISarah Jane Schwarzenberg, Phuong T Vu, Michelle Skalland, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 7, 2018
ECFS best practice guidelines: the 2018 revisionCarlo Castellani, Alistair J A Duff, Scott C Bell, et al.
American Journal of Respiratory and Critical Care Medicine|July 11, 2022
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for <i>F508del</i> and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled StudyMarcus A Mall, Rossa Brugha, Silvia Gartner, et al.
The Lancet. Respiratory Medicine|November 7, 2022
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsNicole Mayer-Hamblett, Felix Ratjen, Renee Russell, et al.
Pediatrics|November 23, 2021
Outcomes of Cystic Fibrosis Screening-Positive Infants With Inconclusive Diagnosis at School AgeTanja Gonska, Katherine Keenan, Jacky Au, et al.
American Journal of Respiratory and Critical Care Medicine|November 16, 2021
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical TrialDavid P Nichols, Alex C Paynter, Sonya L Heltshe, et al.
The Lancet. Respiratory Medicine|September 12, 2023
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspectiveNicole Mayer-Hamblett, John Paul Clancy, Raksha Jain, et al.
HGG Advances|November 17, 2022
High-quality read-based phasing of cystic fibrosis cohort informs genetic understanding of disease modificationScott Mastromatteo, Angela Chen, Jiafen Gong, et al.
Pageof 33